Of mice and men: advances in endothelin research and first antagonist gains FDA approval.
Davenport
Anthony P
AP
Clinical Pharmacology Unit, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, CB2 2QQ, Cambridge, UK. apd10@medschl.cam.ac.uk
Maguire
Janet J
JJ
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D017277:Drug Approval; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D000072396:Endothelin-Converting Enzymes; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008666:Metalloendopeptidases; D051379:Mice; D018345:Mice, Knockout; D017466:Receptors, Endothelin / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D004791:Enzyme Inhibitors; D017466:Receptors, Endothelin; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes